CoLab is pleased to introduce its adjunct representatives.
Uppsala University, Gothenburg University, Stellenbosch University
Capetown Preeclampsia Biobank
Dr. Lina Bergman is an obstetrician-gynaecologist who completed her PhD in 2017 with the title “Cerebral biomarkers in women with preeclampsia” at Uppsala University. She currently holds a 50% postdoctoral position with research conducted at Uppsala University, Gothenburg University and Stellenbosch University. Her main research areas are neurological complications in preeclampsia, early prediction of preeclampsia and prediction of adverse outcome in preeclampsia on the short- and long-term. She is the chair of the Swedish group for guidelines and research in preeclampsia and is currently preparing Swedish guidelines for management of preeclampsia.
IMPACT – Study for Improving Maternal, Pregnancy and Child ouTcomes
Together with a Swedish steering committee, Dr. Bergman is setting up a national cohort study (8 centers) with serum samples in the first trimester of pregnancy to develop a prediction model for preeclampsia in a Swedish setting with an estimated sample size of 30 000 women. The study has started to recruit in October 2018.
Tygerberg Hospital, Stellenbosch University
Cape Town, South Africa
Dr. Cathy Cluver is an obstetrician-gynaecologist and maternal-fetal medicine subspecialist who is completing her PhD on the management and treatment of preterm preeclampsia. She is based at Tygerberg Hospital and Stellenbosch University in Cape Town, South Africa, where she leads the Preeclampsia Research Unit. The Preeclampsia Research Unit has two main arms—Therapeutic trials for novel treatments for preterm preeclampsia and the PReeclampsia Obstetric adVerse Events (PROVE) Biobank.
PROVE (Preeclampsia Obstetric Adverse Events) Biobank
Together with Dr. Berman, Dr. Cluver runs and manages the PROVE biobank with the aim to gain knowledge regarding organ failure in preeclampsia and primarily cerebral and cardiovascular complications. This will be achieved through the establishment of a bio- and databank at Tygerberg Hospital, Stellenbosch University, where longitudinal blood samples, placenta samples, cerebrospinal fluid and cord blood are collected together with a databank consisting of predictors and outcomes in agreement with the COLLECT database and in addition investigations such as MRI brain, estimation of cerebral blood flow through Doppler measurements, MRI heart and echocardiography for women with preeclampsia and organ complications and healthy pregnant controls. The results of the project will hopefully yield a possibility to customize treatment to specific organ involvement, reach new discoveries regarding future drug targets and facilitate surveillance and treatment of women at high risk of mortality and morbidity due to preeclampsia.
Therapeutic trials for novel treatments for preterm preeclampsia:
Together with international researchers, including Professors Sue Walker and Stephen Tong, Dr. Cluver has recently completed her first double blind randomised control trial of 40mg esomeprazole to treat preterm preeclampsia: the Preeclampsia Intervention with Esomeprazole (PIE) trial. 120 women with preterm preeclampsia were recruited in 14 months, plasma and placental samples were collected, analysed and have been stored for further research and detailed pharmacokinetic studies were performed. The team is currently recruiting for a second double blind randomised control trial where 3gm of daily metformin versus placebo is being assessed as a therapeutic for preterm preeclampsia (PI2 trial).
GO-PROVE – Gothenburg Preeclampsia Obstetric Adverse Events
Drs. Bergman and Cluver, together with a team of researchers from Gothenburg University including midwifes, anesthesiologist, radiologists and obstetricians, are setting up a biobank and database with the same predictors and some of the outcomes from PROVE. The project aims to discover new objective biomarkers as predictors for organ impairment in a Swedish setting on short- and long-term and to validate findings from PROVE.
Ahmet Metin Gülmezoglu
World Health Organization (WHO)
Dr A. Metin Gülmezoglu is the coordinator for the maternal and perinatal health and safe abortion team and Research Capacity Strengthening, including the HRP Alliance, at the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, the Department of Reproductive Health and Research, WHO. Dr Gülmezoglu qualified as an obstetrician and gynaecologist in Turkey. He worked as a clinician and researcher in South Africa and obtained his PhD at the University of the Witwatersrand. He then worked at the National Perinatal Epidemiology Unit at Oxford University and at the United Kingdom Cochrane Centre focusing on systematic reviews. In 1998, he joined the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, the Department of Reproductive Health and Research, WHO in Geneva as a medical officer.
Dr Gülmezoglu conducted research on major causes of maternal mortality and morbidity since 1992. He led and contributed to large multicentre randomized controlled trials evaluating promising clinical interventions and improving the quality of maternal and perinatal health care. He is the author of over 30 Cochrane systematic reviews on wide ranging topics including maternal and perinatal health, newborn health, safe abortion techniques, contraception and sexually transmitted infections.
Wayne State University
Detroit, MI, USA
Dr. Korzeniewski is an Associate Professor in the Department of Obstetrics and Gynecology at Wayne State University located in Detroit, Michigan. With a broad multidisciplinary research background, his specific training and expertise is in epidemiology. His research seeks to identify early antecedents of placental dysfunction and related clinical disorders, and to determine the mechanistic pathways that link them to damage to offspring brain structure or functioning. Dr. Korzeniewski came to this line of work after spending several years as an aide for disabled children because he wanted to figure out what causes such suffering and how to prevent it.
Zaleha Abdullah Mahdy
Universiti Kebangsaan Malaysia Medical Center
Kuala Lumpur, Malaysia
Dr. Mahdy graduated from the National University of Malaysia (UKM) in 1989. Between 1993 and 1998, she obtained her membership of the RCOG (1995), Masters in Ob-Gyn from UKM (1996) and Doctor in Medicine (MD) from the University of Newcastle upon Tyne, United Kingdom (1998). Her doctoral research thesis focused on isolation, culture and calcium signaling characteristics of human hand vein endothelial cells in normal pregnancy and preeclampsia, sponsored by a grant from the Royal College of Obstetricians and Gynaecologists, United Kingdom. Preeclampsia and disorders of the placenta are her main areas of interest, along with maternal fetal medicine in general, and nutrition in pregnancy. Her publications include a randomized controlled trial on the role of palm oil vitamin E in prevention of preeclampsia.
In 2012, she completed a three-year term as Deputy Dean of Undergraduate Studies in the UKM medical faculty. After a brief placement as Head of Department of Obstetrics and Gynaecology between 2015 and 2016, she was appointed Dean of the Faculty of Medicine and first female Director of a teaching hospital in Malaysia. Following restructuring of the governance, she is currently the Dean of the Faculty of Medicine besides continuing to function as Professor and Senior Consultant Obstetrician and Gynaecologist. She is a council member of the Malaysian Medical Council. She has 86 published articles in local and international journals, several books and chapters in books, as well as more than 100 abstracts and proceedings. She has been involved in writing the Malaysian Clinical Practice Guidelines (CPG) on Management of Hypertension from the Second Edition until the most recent Fifth Edition 2018 for the Ministry of Health Malaysia.